http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210000402-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d4e15b7ef487e9eb030be8b20717a6b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4706 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_044ee44a6654e42f9fab82280b82966e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bea3acf63308ef6b5de197cb575cb31b |
| publicationDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210000402-A |
| titleOfInvention | Anti-stat3 specific antibody and the pharmaceutical composition comprising thereof |
| abstract | The present invention relates to an anti-STAT3 specific antibody and a pharmaceutical composition comprising the same, and more specifically, to a site that specifically binds to STAT3, further provides a site that specifically binds to STAT3 and an intracellular penetration It relates to an anti-STAT3 specific antibody comprising a DNA binding site and a pharmaceutical composition comprising the same as an active ingredient. The STAT3-specific antibody according to the present invention, particularly the STAT3-specific antibody with STAT3/DNA dual-specific properties, contains a DNA binding site that penetrates into the cell and specifically binds to the DNA in the nucleus. It was confirmed that it can overcome the limitations of the target antibody drug and inhibit its transcription factor activity by specifically binding only to the phosphorylated activated form of STAT3. Side effects for related diseases caused by activation of STAT3 Including the development of therapeutic agents that do not exist, such as the development of therapeutic agents for various carcinomas related to the activation of STAT3, the development of drugs that can inhibit cancer metastasis progressed by activation of STAT3, and rheumatoid arthritis and psoriatic dermatitis caused by activation of STAT3. It may be effectively used in the development of therapeutic agents that do not have side effects for inflammatory diseases or autoimmune diseases. |
| priorityDate | 2019-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 574.